Abbott Laboratories (NYSE:ABT) last session’s volume of 5 million shares was lower than its average volume of 5.56 million shares. The stock, after opening at $54.78, hit $54.83 through the close by scoring -0.33%.Abbott Laboratories (ABT) Analyst Opinion
Abbott Laboratories has a consensus outperform rating from 19 Wall Street analysts, and the number of shares currently sold short amount to at least 0.7% of shares outstanding. The stock sank -0.42% last month and is up 42.75 this year. Wall Street is only getting more bullish on the stock, with 13 of analysts who cover ABT having a buy-equivalent rating. Analysts have placed a $61.47 price target on Abbott Laboratories, suggesting a 12.11% gain from recent close. It’s currently trading about -3.27% below its 52-week high.
Abbott Laboratories (ABT) surprised the stock market in its last reported earnings when it earned $0.66 a piece versus the consensus-estimated $0.65. Its revenue totaled $6.72 billion up 1.2% from the previous quarter.Abbott Laboratories (NYSE:ABT) Intraday View
This stock (ABT) is ahead of its 52-week low with 46.68%. Its last month’s stock price volatility remained 1.22% which for the week stands at 1.36%. The share price has moved backward from its 20 days moving average, trading at a distance of -0.69% and stays 1.6% away from its 50 days moving average. Over the last five days, shares have faced -0.76% losses and now is up 13.75% since hitting its 200-day moving average of $49.94. Abbott Laboratories (ABT) has made its way to a 12-month gain of 37.73%.
Turning to Clovis Oncology, Inc. (NASDAQ:CLVS), its shares were trading at $64.56 a retreat of $-0.93, on the trading floor. The stock, after opening at $63.62, touched a high of $65.75 before paring much of its gains. So far, analysts are sticking with their neutral recommendations with the consensus call at 2. Clovis Oncology, Inc. has 4 buy ratings, 4 holds and 0 sells even after the stock tumbled -35.08% from its high of $99.45 to a $3.18 billion market value through last close.
The company’s consensus rating on Reuter’s scale remained unchanged from 2 to 2 during a month. Analysts set a 12-month price target of $92.58 a share. The target implies a 43.4% spike from where the shares are currently trading. Also, the current price highlights a discount of 93.62% to analysts’ high consensus price target.Clovis Oncology, Inc. (NASDAQ:CLVS) Intraday Trading
The counter witnessed a trading volume of 1.12 million shares versus an average volume of 1.45 million shares during last trading session. Its last month’s stock price volatility remained 3.84% which for the week approaches 4.41%. The lowest price the stock reached in the last trading day was $63.17 and compares with the $33.23 52-week low. The stock recovered 94.28% since its low point and has performed 45.34% year-to-date.